Lidocaine Attenuates the Development of Diabetic-Induced Tactile Allodynia by Inhibiting Microglial Activation | Zendy

Naoko Suzuki | Zendy; Maiko HasegawaMoriyama | Zendy; Yoshika Takahashi | Zendy; Yuji Kamikubo | Zendy; Takashi Sakurai | Zendy; Eiichi Inada | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lidocaine Attenuates the Development of Diabetic-Induced Tactile Allodynia by Inhibiting Microglial Activation

Author(s) -

Naoko Suzuki,

Maiko HasegawaMoriyama,

Yoshika Takahashi,

Yuji Kamikubo,

Takashi Sakurai,

Eiichi Inada

Publication year - 2011

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e31822827a2

Subject(s) - medicine , lidocaine , allodynia , anesthesia , microglia , hyperalgesia , neuroscience , pharmacology , nociception , inflammation , receptor , biology

Lidocaine is used clinically for tactile allodynia associated with diabetes-induced neuropathy. Although the analgesic effect of lidocaine through suppression of microglial activation has been implicated in the development of injury-induced neuropathic pain, its mechanism of action in diabetes-induced tactile allodynia has not yet been completely elucidated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research